One of the most debilitating neurological complications of human immunodeficiency virus (HIV), affecting nearly one in three patients, is painful peripheral neuropathy. Although HIV infection can cause distal sensory polyneuropathy (DSP), the advent of highly active antiretroviral therapy (HAART) to treat HIV infection has resulted in a significant number of patients developing a clinically indistinguishable form of toxic neuropathy. The predominant symptom, regardless of etiology, is excruciating unremitting pain, resistant to pharmacological treatments, that leads to a reduction in the ability to conduct activities of daily living and, eventually, inability to ambulate. Since withdrawal from nucleoside therapy is not typically recommended, a more thorough understanding of the etiology and pathophysiology underlying nucleoside-induced peripheral neuropathy, through basic and clinical research endeavors, will aid in the development of new therapeutic treatments aimed at alleviating or ameliorating pain. This article provides the latest information regarding the pathophysiology and clinical implications of HIV peripheral neuropathy.
Skip Nav Destination
HIV: A Chronic IllnessWith Emerging Issues| January 01 2006
HIV Peripheral Neuropathy: Pathophysiology and Clinical Implications
Susan G. Dorsey, PhD, RN;
From the School of Nursing, University of Maryland, Baltimore.
Request reprints to Susan G. Dorsey, Assistant Professor, University of Maryland, Baltimore School of Nursing, Room 764, 655 West Lombard Street, Baltimore, MD 21201 (firstname.lastname@example.org).
Search for other works by this author on:
AACN Adv Crit Care (2006) 17 (1): 30–36.
- Views Icon Views
- Share Icon Share
Susan G. Dorsey, Patricia Gonce Morton; HIV Peripheral Neuropathy: Pathophysiology and Clinical Implications. AACN Adv Crit Care 1 January 2006; 17 (1): 30–36. doi:
Download citation file: